Please login to the form below

Not currently logged in
Email:
Password:

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

AZ

AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a compelling argument that the drug should be use ahead of other dugs in the class in newly-diagnosed patients.

The company says post-progression data - which evaluates the time between disease progression on the first-line therapy to the start of second- or late-line therapy - reinforces the benefit of using Tagrisso (osimertinib) first-line in EGFR-mutated non-small cell lung cancer (NSCLC).

Earlier data from FLAURA have shown that AZ’s drug improved progression-free survival (PFS) versus older EGFR inhibitors erlotinib (Roche’s Tarceva) and gefitinib (AZ’s Iressa), and has supported regulatory filings as a front-line therapy for EGFR-mutated NSCLC.

Tagrisso is already on the cusp of blockbuster sales status after becoming the standard for second-line treatment, but the prospect of approval in previously-untreated patients has stimulated debate about the best order to deliver EGFR drugs, as they all eventually succumb to resistance and lose efficacy over time.

The new results indicate that when Tagrisso is given first-line, it almost halves the risk of a second progression or death compared to Tarceva and Iressa, according to Sean Bohen, AZ’s chief medical officer.

In the analysis, the median time to first subsequent therapy or death was 23.5 months for patients treated with Tagrisso, compared to 13.8 months for those on erlotinib or gefitinib. Moreover, fewer patients on first-line Tagrisso discontinued treatment than in the comparator arm, and just 29% needed a subsequent treatment compared to 46% on erlotinib or gefitinib.

“These findings build on the clinically-meaningful PFS benefit of Tagrisso and reinforce its potential as a new standard of care,” said Bohen. Unlocking the market for previously-untreated EGFR-mutated NSCLC is seen as central to AZ’s ambitions for Tagrisso, which is one of its top growth prospects.

In making the case for Tagrisso AZ acknowledges that post-progression data isn’t a wholly recognised endpoint in cancer studies, which generally focus on PFS and overall survival (OS) data.

In a blog post, the company’s global clinical lead for oncology, Yuri Rukazenkov, said that while OS remains the gold-standard measure of efficacy in cancer, using post-progression data can not only help researchers to establish whether a drug should be used first or later in the treatment schedule, but “can also establish the optimal sequence of treatment - and this can have a real impact on patient outcomes”.

Article by
Phil Taylor

16th April 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics